This chapter focuses on the base excision repair (BER) pathway which is responsible for the repair of single-base lesions and can be reconstituted in vitro with a glycosylase, AP endonuclease, polymerase β, and a ligase. BER is the predominant pathway for the repair of oxidative and alkylation DNA damage as well as a basic or baseless sites. Without this balance of enzymatic activities, incomplete processing of the damage occurs, repair intermediates accumulate, and eventually cells will die. Inhibition of proliferation and cell death are desirable in tumor cell populations, therefore inhibitors of BER proteins are under development and currently being evaluated in the clinic. Several of these agents are being evaluated in combination with numerous existing chemotherapeutic agents and radiation therapy. Combination therapy with agents that generate DNA damage that is repaired by BER is reasonable and demonstrating efficacy both preclinically and in early clinical trials.
|Original language||English (US)|
|Title of host publication||DNA Repair in Cancer Therapy|
|Number of pages||25|
|State||Published - Dec 1 2012|
ASJC Scopus subject areas